Globus Medical arrives at its August 4 earnings report with the Street quietly downgrading its expectations — even as options traders have swung to their most bullish positioning of the past year.
The analyst picture has shifted materially since the May selloff. Multiple firms trimmed price targets through July: Truist cut from $115 to $100 while keeping a Buy, RBC came down from $120 to $115 on an Outperform, and Stifel lowered to $80 on a Hold. UBS initiated just days ago at Neutral with an $82 target — essentially a valuation ceiling at current prices. The consensus mean target has settled around $104, implying modest upside from the $78.79 close, but the direction of travel is unmistakably lower. The analyst recommendation factor score ranks in the 94th percentile, meaning GMED's relative recommendation profile remains comparatively strong — the cuts are trimming ambition, not reversing conviction.
The bull and bear cases are sharply delineated heading in. Bulls point to organic revenue growth, expanding EPS guidance, robotic systems adoption, and a five-year EBIT CAGR near 24% — a genuine growth story trading at roughly 16x trailing earnings and an EV/EBITDA of 9.3x that has compressed over the past month. Bears focus on Nevro integration drag, margin pressure from commercial restructuring, and the bear-case scenario that effectively prices the stock near current levels on flat margin assumptions. The last two prints both ended badly: the May release produced a 12.6% single-day drop and a further 13.5% five-day slide, with the prior quarter delivering a 16% five-day loss.
What makes the setup genuinely interesting is the divergence between short positioning and options sentiment. Short interest has pulled back from its July 23 peak — down about 7% on the week to 6.3% of the free float — suggesting some shorts covered into the rally that lifted the stock 3% over the past week. Borrow remains freely available at 608% availability and a cost to borrow near 0.5%, so there is no squeeze dynamic at work. Yet options tell the opposite story: the put/call ratio has collapsed to 0.14, nearly a full standard deviation below its 20-day average and close to the lowest reading of the past year. Call positioning this aggressive into a name with two consecutive double-digit post-earnings drops is a notable contrast — it implies either strong conviction in an upside surprise or, at minimum, a market that has stopped hedging for downside.
The August 4 print is therefore less a test of whether Globus Medical can grow and more a test of whether it can demonstrate margin recovery from Nevro integration costs at a pace that justifies the call-side optimism the options market has priced in.
See the live data behind this article on ORTEX.
Open GMED on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
